Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer
Interventions: DRUG: Trastuzumab Deruxtecan|DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: cyclophosphamide
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo